Collagen Solutions entered into a new minimum three-year agreement with NovaBone Products, manufacturer of FDA 510(k)-cleared synthetic bone grafts.
The companies have worked together since 2015 to develop and supply specialized collagen biomaterials to create bone graft products used in orthopedic and dental applications. This transaction formalizes a longer-term supply arrangement to ensure that NovaBone has consistent, increased access to these biomaterials to support its continued growth.
NovaBone's product lineup includes irrigation-resistant IRM™ grafting material, bioactive Strip Bone Graft, MacroFORM™ collagen bioactive glass scaffold and NovaBone Putty.
In January, Halma Plc acquired NovaBone to enhance its own presence in the orthopedic market and biologics segment. Halma is a diversified global group of life-saving technology companies.
Jamal Rushdy, CEO of Collagen Solutions, said, "We are excited by NovaBone’s growth prospects and new backing by Halma to accelerate their growth plans. Both companies have worked collaboratively over the past several years to optimize a collagen formulation that meets the specific demands of NovaBone’s unique technology. We look forward to continuing to support our long-standing partner through their next phase of growth."
Art Wotiz, President of NovaBone, said, "NovaBone is well positioned within the fast-growing orthobiologics market segment. Our line of bone graft biomaterials harnesses the body's natural healing process to accelerate bone healing, serving an important clinical need that is fuelling our growth. We are pleased to have Collagen Solutions as a long-term partner to support us along the journey."